4 ms·
As somebody who has worked in genomics for decades, I don't really see progress in DNA sequencing as being motivated by extrinsic factors. Put another way, the
by dekhn 7y ago
As somebody who has worked in genomics for decades, I don't really see progress in DNA sequencing as being motivated by extrinsic factors. Put another way, there really isn't enough scientific discovery being driven by new sequence data to justify the spending. Many articles have been written claiming that sequencing is going to revolutionize medicine. It's been a very useful research tool, and some genomics has been very valuable medically, but it doesn't live up to the hype.
- nknealk 7y agoTo add to this, I worked in melanoma genomics for 2 years. Off the top of my head I cannot think of a single cancer drug on the market who's target was discovered through NGS. It was great as a research tool. But I have yet to see it improve patient outcomes
- avani 7y agoIt's not quite _discovering_ a target from NGS, but lots of existing cancer drugs are targeted based on genotyping tumours. Breast cancer is the classic one, where, say, if you can quickly determine if your sample is Her2+ your treatment plan drastically changes. Now, getting enough cancer cells in your tumour sample to reliably genotype at that stage is a separate hard problem.